Patients on multiple daily injections (MDI) insulin therapy and Dexcom CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1
Medicare now provides coverage for therapeutic CGM systems (those approved for use in making diabetes treatment decisions). The Dexcom G5® Mobile CGM System is the first and only mobile-enabled CGM system covered as a Medicare benefit.
Dexcom is pleased to sponsor a quarterly podcast series to complement Diabetes Technology & Therapeutics. The podcast series features prominent medical doctors and certified diabetes educators discussing continuos glucose monitoring (CGM),...
Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.